Kadmon Holdings Inc.

Plus: Ochre appoints Forster as chairperson and updates from Women In Bio, Verismo and MIG

Why Ovid and Sam Waksal newco Graviton are first tackling a rare seizure disorder with a target that may have a role in diverse indications

Over half of the cancer therapies Chinese companies out-licensed in 2021-22 employ new modalities or unapproved targets

Plus FDA vaccine and cell therapy adcomms scheduled, and updates from Full Life and Xueji Bio

The firm is back to picking stocks in a down market, but benefiting from years of diversification

Plus: Molecular glue play Triana debuts and updates from AZ-Harbour, BioXcel, Citius, Novartis, Sanofi

Plus Faga replaces Suria as Anaptys CEO and updates from Mozart, Longboard, Capsida, Phathom and more

Half the field is stuck in first gear, but a wealth of bispecifics, novel technologies are bringing new energy

Addition of anti-CSFR1 axatilimab complements Jakafi in Incyte’s portfolio

Clover readies COVID vaccine for submission, plus Veklury, Xalkori, Hexagon, Paige, Astellas, Rhythm